LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "hypomethylating agent" as a keyword



Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony‐stimulating factor chemotherapy as a first‐line therapy for newly diagnosed acute myeloid leukemia: A propensity score–matched analysis

Sign Up to like & get
recommendations! Published in 2024 at "Cancer"

DOI: 10.1002/cncr.35278

Abstract: Both venetoclax plus a hypomethylating agent (VEN/HMA) and cytarabine, aclarubicin, and granulocyte colony‐stimulating factor (CAG) are low‐intensity regimens for older patients with acute myeloid leukemia (AML) that show good efficacy and safety. It is unknown… read more here.

Keywords: aclarubicin granulocyte; venetoclax plus; hypomethylating agent; cytarabine aclarubicin ... See more keywords

Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study

Sign Up to like & get
recommendations! Published in 2024 at "Annals of Hematology"

DOI: 10.1007/s00277-024-05623-0

Abstract: Very few data are available about hypomethylating agent (HMA) efficiency in core binding factor acute myeloid leukemias (CBF-AML). Our main objective was to evaluate the efficacy and safety of HMA in the specific subset of… read more here.

Keywords: hypomethylating agent; core binding; cbf; cbf aml ... See more keywords
Photo by bermixstudio from unsplash

How I treat MDS after hypomethylating agent failure.

Sign Up to like & get
recommendations! Published in 2019 at "Blood"

DOI: 10.1182/blood-2018-03-785915

Abstract: Hypomethylating agents (HMA) azacitidine and decitabine are standard of care for myelodysplastic syndrome (MDS). Response to these agents occurs in ∼50% of treated patients, and duration of response, although variable, is transient. Prediction of response… read more here.

Keywords: hypomethylating agent; hma failure; treat mds; mds hypomethylating ... See more keywords

Venetoclax plus hypomethylating agent as first- and second-line treatment in patients with AML: A single-center experience

Sign Up to like & get
recommendations! Published in 2025 at "Blood"

DOI: 10.1182/blood-2025-6988

Abstract: Venetoclax combined with a hypomethylating agent is the standard of care for patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy; it has also become widely used in the relapsed/refractory… read more here.

Keywords: treatment; hypomethylating agent; risk; aml ... See more keywords

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.

Sign Up to like & get
recommendations! Published in 2018 at "Blood advances"

DOI: 10.1182/bloodadvances.2018015529

Abstract: Hypomethylating agent (HMA) failure in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) carries a poor prognosis with limited treatment options. Although intensive, remission induction chemotherapy is often used subsequently, in particular to bridge to… read more here.

Keywords: hypomethylating agent; hma failure; myeloid leukemia; acute myeloid ... See more keywords
Photo by nci from unsplash

Response to induction or hypomethylating agent therapy among patients with myeloproliferative neoplasms progressing to accelerated or leukemic phase.

Sign Up to like & get
recommendations! Published in 2017 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2017.35.15_suppl.e18561

Abstract: e18561Background: Post-myeloproliferative neoplasm (MPN) acute myeloid leukemia (AML) and accelerated phase disease (AP) are associated with poor outcomes; the optimal management of these patients ... read more here.

Keywords: therapy among; hypomethylating agent; among patients; agent therapy ... See more keywords
Photo by nci from unsplash

Hypomethylating agent (HMA) treatment as a bridge to allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory acute myeloid leukemia (RR-AML).

Sign Up to like & get
recommendations! Published in 2018 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2018.36.15_suppl.7033

Abstract: 7033Background: Outcomes for patients (pts) with RR-AML are poor, with limited treatment options. Salvage HMA therapy has been explored for RR-AML but is often considered palliative. We examined re... read more here.

Keywords: treatment bridge; hypomethylating agent; treatment; hma treatment ... See more keywords
Photo by nci from unsplash

Methylation profiling of hypomethylating agent response and treatment failure in pediatric and young adult MDS/AML.

Sign Up to like & get
recommendations! Published in 2020 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2020.38.15_suppl.e22502

Abstract: e22502Background: Hypomethylating agents (HMAs) have favorable toxicity profiles and anti-leukemia activity in adult AML/MDS. We previously reported similar activity in eight pediatric patients (Ph... read more here.

Keywords: profiling hypomethylating; adult; hypomethylating agent; methylation profiling ... See more keywords

Integrative Analyses Reveal the Anticancer Mechanisms and Sensitivity Markers of the Next-Generation Hypomethylating Agent NTX-301

Sign Up to like & get
recommendations! Published in 2023 at "Cancers"

DOI: 10.3390/cancers15061737

Abstract: Simple Summary We thoroughly investigated the experimental and preclinical efficacy of the novel hypomethylating agent (HMA) NTX-301 through comparative analyses with conventional HMAs. By performing multiomics data analyses, we demonstrated the mechanisms of action underlying… read more here.

Keywords: sensitivity; ntx 301; hypomethylating agent; efficacy ... See more keywords